Dr. Li's long term goal is to understand the molecular mechanism of mismatch repair (MMR) and its role in cancer avoidance. MMR is a mutation avoidance system and plays an important role in maintaining genetic stability. It has been shown that defects in the human system confer a strong cancer predisposition including hereditary polyposis colorectal cancer. Environmental carcinogens covalently modify DNA to form carcinogen-DNA adducts, which induce mutations that initiate carcinogenesis. Recently, MMR components have been shown to recognize certain forms of carcinogen-DNA adducts that are previously thought to be only processed by nucleotide excision repair (NER). It is also documented that MMR-proficient cells are much more sensitive to the cytotoxic effects of N-methyl-N'-nitro-nitrosoguanidine (MNNG) compared to MMR-deficient cells. Given these findings, we hypothesize that MMR components either directly participate in repair of carcinogen-DNA adducts or function as a sensor to activate programmed cell death. To test this hypothesis, four lines of work are proposed in this application. First, using an electrophoretic mobility shift assay, purified hMutSa, a human mismatch recognition protein, will be tested for its ability to bind oligonucleotide duplexes containing site-specific adducts of acetylaminofluorene, benzo[a]pyrene diol epoxide, and MNNG, the three most critical chemical carcinogens. Second, cell extracts derived from tumor cells with different MMR backgrounds will be examined to process circular plasmid DNA containing site-specific adducts of the carcinogens listed above. Third, to investigate the physiological importance of the recognition and processing of carcinogen-DNA adducts by MMR, MMR-normal and mutant cells will be treated with carcinogens listed above or transfected with carcinogen-modified pZ189 plasmid, an SV40-based shuttle vector, and analyzed for apoptosis. Since MNNG-induced cell death of MMR-proficient cells has been attributed to their futile attempts to remove MMNG adducts in the template DNA strand, it is anticipated that replication of carcinogen-modified genomic or plasmid DNA will induce apoptosis in MMR-proficient cells. Finally, to determine if carcinogen adducts can be remove in vivo by MMRcriti, genomic DNA from MMR-proficient and MMR-deficient cells that are treated with carcinogens will be digested into mononucleosides, and followed by adduct detection and quantitation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA072956-02
Application #
2748899
Study Section
Chemical Pathology Study Section (CPA)
Program Officer
Okano, Paul
Project Start
1997-08-01
Project End
2002-07-31
Budget Start
1998-08-01
Budget End
1999-07-31
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Kentucky
Department
Pathology
Type
Schools of Medicine
DUNS #
832127323
City
Lexington
State
KY
Country
United States
Zip Code
40506